The problem of pressure elevation associated with intravitreal triamcinolone

British Journal of Ophthalmology

Volumn 90, Issue 8, 2006, Pages 934-935

  Conway, Mandi D ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISOLONE ACETATE; TRIAMCINOLONE;

DIABETIC MACULAR EDEMA; DISEASE ASSOCIATION; DOSE RESPONSE; EDITORIAL; EYE INFECTION; HUMAN; INTRAOCULAR HYPERTENSION; NEOVASCULAR GLAUCOMA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; VISUAL IMPAIRMENT;

ANTI-INFLAMMATORY AGENTS; GLUCOCORTICOIDS; HUMANS; OCULAR HYPERTENSION; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 33746565335     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.093310     Document Type: Editorial

References (47)

1. McCuen B, Bressler N, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-8.
2. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996;103:2099-104.
3. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26:277-81.
4. Martidis A, Miller DG, Ciulla TA, et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 1999;15:425-8.
5. Martidis A, Duker JS, Greenberg PB. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7.
6. Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina 2003;23:113-16.
7. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-6.
8. Conway MD, Canakis C, Livir-Rallatos C, et al. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 2003;29:27-33.
9. Benhamou N, Massin P, Haouchine B, et al. Intravitreal triamcinolone for refractory pseudophakic macular edema. Am J Ophthalmol 2003;135:246-9.
10. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 2003;136:384-6.
11. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003;121:667-73.
12. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7.
13. Karacorlu M, Ozdemir S, Karacorlu S. Intravitreal triamcinolone acetonide for the treatment of chronic pseudophakic cystoid macular oedema. Acta Ophthalmol Scand 2003;81:648-52.
14. Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol 2003;136:419-25.
15. Rechtman E, Allen VD, Danis RP, et al. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003;136:739-41.
16. Jonas JB, Kreissig I, Degenring RF. Intravitreal triamcinolone acetonide as treatment of ischemic ophthalmopathy. Eur J Ophthalmol 2003;13:575-6.
17. Andrade RE, Muccioli C, Farah ME, et al. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004;137:572-4.
18. Ciardella AP, Klancnik J, Schiff W, et al. Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 2004;88:1131-6.
19. Degenring RF, Kreissig I, Jonas JB. Intraocular triamcinolone for diffuse diabetic macular edema. Ophthalmologe 2004;101:251-4.
20. Ip MS, Gottlieb JL, Kahana A. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004;122:1131-6.
21. Jonas JB, Akkoyun I, Budde WM, et al. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004;122:218-22.
22. Jonas JB, Degenring RF, Kamppeter BA. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol 2004;138:158-60.
23. Jonas JB, Degenring RF, Kreissig I. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 2004 June 25.
24. Jonas JB. Intraocular availability triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:560-2.
25. Bashshur ZF, Ma'luf RN, Allam S, et al. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 2004;122:1137-40.
26. Karacorlu M, Ozdemir H, Karacorlu S, et al. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema. Eye 2004 Aug 13.
27. Lam DS, Chan CK, Tang EW, et al. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clin Experiment Ophthalmol 2004;32:509-72.
28. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-24.
29. Ozkiris A, Evereklioglu C, Erkilic K, et al. Intravitreal triamcinolone acetonide injection as primary treatment for diabetic macular edema. Eur J Ophthalmol 2004;14:543-9.
30. Rechtman E, Danis RP, Pratt LM, et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 2004;88:344-7.
31. Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovasculorization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 2004;138:884-5.
32. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003;110:1517-25.
33. Micelli Ferrari T, Sborgia L, Furino C, et al. Intravitreal triamcinolone acetonide: valuation of retinal thickness changes measured by optical coherence tomography in diffuse diabetic macular edema. Eur J Ophthalmol 2004;14:321-4.
34. Smithen LM, Ober MD, Maranan L, et al. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004;138:740-3.
35. Bhavan S, Peyman GA, Conway MD, et al. Intraocular pressure after low-dose 400 μg intravitreal triamcinolone acetonide injection. ARVO abstract 2004: 3945/B406.
36. Conway MD, Peyman GA, Bhavan S, et al. Predictive value of low-dose intravitreal triamcinolone acetonide for steroid responders. ARVO Abstract 2005: 137/B111.
37. Kahook M, Olson JL, Mandava N. Incidence of increased intraocular pressure after intravitreal triamcinolone acetonide injection. ARVO Abstract 2005: 135/B109.
38. Feistmann JA, Neelakantan A, Vaishnav MD, et al. topical steroid challenge prior to intravitreal kenalog injection: does it prevent IOP spikes? ARVO Abstract 2005: 1432/B201.
39. Spandau UH, Derse M Schmitz-Valckenberg P, et al. Dosage dependency of intravitreal triamcinolone acetonide as treatment of diabetic macular oedema. Br J Ophthalmol 2005;89:999-1003.
40. Jonas JB, Kreissig I, Denenring R. Intravitreal triamcinolone acetonide for the treatment of intraocular proliferative, exudative and neovascular diseases. Prog Retin Eye Res 2005;24:587-611.
41. Park HY, Yi K, Kim HK. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Korean J Ophthalmol 2005;19:122-7.
42. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide. Ophthalmology 2005;112:538-8.
43. Kreissig I, Degenring RF, Jonas JB. [Diffuse diabetic macular edema. Intraocular pressure after intravitreal triamcinolone acetonide]. Ophthalmologe 2005;102:153-7.
44. Jonas JB. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil. Br J Ophthalmol 2002;86:1450-1.
45. Jonas JB. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am J Ophthalmol 2004;137:560-2.
46. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Ophthalmol Scand 2005;83:645-63.
47. Rhee DJ, Peck RE, Belmont J, et al. Intraocular pressure alterations following intravitreal triamcinolone acetonide. Br J Ophthalmol 2006;90:999-1003.